Bordeaux PharmacoEpi Festival 2019

La BPE a créé un Festival de la discipline de très haut niveau : le Bordeaux PharmacoEpi Festival, qu’elle organise depuis 2010 (huit éditions du Festival ont eu lieu à ce jour).
Durant trois jours, six experts en pharmaco-épidémiologie de renommée mondiale viennent exposer le sujet de leur choix, au cours d’une demi-journée chacun.
Ce format original de niveau master class permet à l’équipe BPE et également à tous les participants d’être en première ligne sur les actualités majeures de la discipline ainsi que sur ses hot topics.

Edition 2020
Don’t forget the 9th Bordeaux PharmacoEpi Festival,

expected on May, 2020

Over three days, six world-class experts will come to Bordeaux to talk of the topic of their choice.

Good Science, good Wine, good Fun!

More information soon on this page.

Edition 2019
Catherine Quantin
Dijon
The validity of diagnoses in public health databases (with invited speakers)
Tania Schink
Bremen, Germany
Internal validation of outcomes in public health databases
Giuseppe Traversa
Rome, Italy
Governing pharmaceutical care: Do we need to worry about the "excessive" prices of drugs? A pharmacoepidemiologist perspective
Gianluca Trifiró
Messine, Italy
Challenges in postmarketing surveillance of biologics in the era of biosimilars
Bernard Bégaud
Bordeaux
[General Public Conference] A quoi peut servir la pharmacoépidémiologie ?
Kristian B. Filion
Montreal, Canada
The safety of antidiabetic drugs, and Distributed Drug Safety Networks/CNODES
Ron Herings
Amsterdam, NL
Scenario and prediction modeling In pharmacoepidemiology for health personalization
Edition 2018
Munir Pirmohammed
Liverpool, UK
The excitement and challenges of being a clinical pharmacologist
Jacques Le Lorier
Quebec, CA
The Pharmacologically Pertinent Period of Effect. Are the editors doing their job ?
Susana Perez-Gutthann
Barcelona
Looking behind the code
Corinne de Vries
London, UK
Drug safety in pregnancy
Tom Walley
Liverpool, UK
Clinical research in the UK
John Ioannidis
Stanford, USA
Reproducible and useful epidemiology: why and how
Edition 2017
Andy Stergachis
Seattle, USA
How to communicate benefits and risks, based on pharmacoepidemiological studies
Jesper Hallas
Odense - Denmark
Pharmacovigilance in low- and middle-income countries: need, issues, methods, case studies, and future directions.
Gerard de Pouvourville
Paris
Pharmacoeconomics in the modern world.
Til Stürmer
North Carolina, USA
Principled versus pragmatic pharmacoepidemiology: do we need to take sides?
Jaime Caro
Boston, USA
The use of DICE simulation for epidemiologic models
Marc Rodwin
Boston, USA
1) How can inappropriate off-label drug use be managed?
2) Financial relations between pharmaceutical firms and physicians
Edition 2015
Arnold Chan
Taipei, Taiwan
Pharmacoepidemiology and drug safety in Asia.
Jerry Avorn
Boston, USA
Patients, doctors and drug safety
Sonia Hernandez-Diaz
Boston, USA
Are babies the only outcomes in pregnancy?
Stella Blackburn
London, UK
Considerations on risk-benefit assessment
Bert Leufkens
Utrecht, NL
Pharmacovigilance is here to stay
Edition 2014
Saad Shakir
Boston, USA
Risk Management in Pharmacovigilance: what is under the bonnet?
Joshua Gagne
Boston, USA
Disease risk scores in pharmacoepidemiology?
Patrick Ryan
Philadelphia, USA
Lessons in pharmacoepidemiology from the Observational Medical Outcomes Partnership
Martijn Schuemie
Rotterdam, NL
More Lessons in pharmacoepidemiology from the Observational Medical Outcomes Partnership
Morten Andersen
Stockholm, Suède
How things happen in the Nordic countries?
Darren Toh
Boston, USA
Prospective surveillance of newly approved medical products
Edition 2013
Nancy Dreyer
Boston, USA
Observational Studies of Effectiveness and Safety: Practical Applications and Challenges
Ken Rothman
Boston, USA
Ten Persistent Research Fallacies1. The randomized trial represents the perfect study design.2. Results from case-control studies are weaker than those from cohort studies, and the results from cohort studies are weaker than those from randomized trials.3. Study subjects should be representative of target populations.4. When measuring rates, the person-time of exposure to an agent goes in the denominator.5. The control group in ca-co studies should be just like the cases except that they don't have disease.
Ken Rothman
Boston, USA
Ten Persistent Research Fallacies (cont'd)6. When conducting multiple comparisons, take the number of comparisons into account when obtaining p-values.7. Account for missing data with an indicator term for "missingness" in a model8. A good way to categorize a variable is by quartiles or quintiles 9. A reasonable way to interpret data is by using significance tests10. Report power when reporting the results of a study.
Samy Suissa
Montreal, Canada
Time-related biases in pharmacoepidemiology: Randomized trials built on sand.
Jacques Benichou
Rouen
Attributable and competitive risks in pharmacoepidemiology
Edition 2011
Syd Shapiro†
Capetown,
South Africa
Oligognostic mega-analysis. Is Archie turning in his grave?
Michal Abrahamowicz
Montreal, Canada
Modeling the effects of time-varying drug exposures: alternative models, cumulative effects and further challenges
Olaf Klungel
Utrecht,
The Netherlands
Improved control for confounding using propensityscores and instrumental variables
Jeremy Rassen
Boston, USA
Computational pharmacoepi - the frontier between computing and PE
Tobias Kurth
Paris/Bordeaux
The evaluation of different treatment effects in subgroups: practical uses of propensity scores
Bernard Bégaud
Bordeaux
« Who cares about The truth? Non-comparative comparisons are safer », the Guru says.
Edition 2010
Tom MacDonald
Dundee, Scotland
A rant about everything that irritates me including data protection, privacy, consent, regulation and ethics, interspersed with singing, art, poetry, philosophy (home-spun and otherwise), fantasy worlds (where are we now) and perfect worlds (will we ever get there?) a bit about risks (to individuals) and benefits (to society), duty of care, politics, changing the world, how we and ISPE can do this and other random thoughts including expressing ideas that are not my own or new and more singing".
Yola Moride
Montreal – Canada
Why do I bother doing teleconferences in the middle of the night for data safety monitoring boards when nobody cares about denominators?
Stephen Evans
London UK
Pharmacoepidemiology and the pharmaceutical industry: undermined by their lawyers & tarnished by their funding?
Judith K Jones
Fairfax, Degge group, USA
The smorgasboard of exposure options- drugs, biologics, vaccines, devices --how long do you count the biological effect in a population study...?
Miriam Sturkenboom
Rotterdam, NL
The european database festival:one happy family?
Alexander Walker
Boston, USA
Signal Detection